title: A single-institute phase I/II trial combining nedaplatin dose escalation with a fixed dose of docetaxel for induction chemotherapy of oral squamous cell carcinoma.
abstract: The purpose of this clinical trial was to assess the toxicity and efficacy of docetaxel plus nedaplatin induction chemotherapy in patients with locally advanced oral squamous cell carcinoma (OSCC). Twenty-one patients were enrolled in this phase I/II clinical study. The toxicities, response rates, and the maximum tolerated dose of nedaplatin that could be safely given preoperatively were assessed. Patients received escalating doses of nedaplatin (60, 70, 80, 90 mg/m2) combined with a fixed dose of docetaxel (60 mg/m2) on day one. Dose-limiting toxicity (DLT), grade 4 leukopenia lasting for two days or more, was seen in one patient at dose level 3; no other DLT was observed at any dose level. The overall response rate was 66.7%. The response rate was 100% at nedaplatin dose level 4, while that at dose level 1 was low (33.3%). Given these results, the recommended dose of nedaplatin in this regimen combined with fixed dose docetaxel (60 mg/m2) was determined to be 90 mg/m2. Docetaxel 60 mg/m2 plus nedaplatin 90 mg/m2 induction chemotherapy can be recommended for patients with locally advanced oral squamous cell carcinoma. Based on these results, an early phase II clinical study using this dose level was conducted; docetaxel plus nedaplatin induction chemotherapy appears to be a useful regimen for the treatment of OSCC. A late phase II clinical study is warranted.
authors.affiliation: Department of Oral Surgery, Sapporo Medical University School of Medicine, South-1, West-16, Chuo-ku, Sapporo 060-8543, Japan. amiyazak@sapmed.ac.jp <amiyazak@sapmed.ac.jp>
authors.forename: Akihiro
authors.initials: A
authors.lastname: Miyazaki
authors.forename: Junichi
authors.initials: J
authors.lastname: Kobayashi
authors.forename: Takashi
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Yukie
authors.initials: Y
authors.lastname: Kido
authors.forename: Kanako
authors.initials: K
authors.lastname: Takemura
authors.forename: Masato
authors.initials: M
authors.lastname: Abe
authors.forename: Kei
authors.initials: K
authors.lastname: Tomihara
authors.forename: Hironari
authors.initials: H
authors.lastname: Dehari
authors.forename: Kenji
authors.initials: K
authors.lastname: Nakamori
authors.forename: Itaru
authors.initials: I
authors.lastname: Nagai
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Hiratsuka
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control*; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D012074:Remission Induction; D043823:Taxoids / Q000008:administration & dosage* / Q000009:adverse effects